AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
相关临床试验
35
25 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2005
进行中（未招募）
24
68.6%
已完成
4
11.4%
尚未招募
1
2.9%
招募中
4
11.4%
终止
1
2.9%
Unknown
1
2.9%
暂无批准数据
暂无资讯文章
